Tseng Hung Fu, Schmid D Scott, Harpaz Rafael, LaRussa Philip, Jensen Nancy J, Rivailler Pierre, Radford Kay, Folster Jennifer, Jacobsen Steven J
Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena.
Clin Infect Dis. 2014 Apr;58(8):1125-8. doi: 10.1093/cid/ciu058. Epub 2014 Jan 26.
We report the first laboratory-documented case of herpes zoster caused by the attenuated varicella zoster virus (VZV) contained in Zostavax in a 68-year-old immunocompetent adult with strong evidence of prior wild-type VZV infection. The complete genome sequence of the isolate revealed that the strain carried 15 of 42 (36%) recognized varicella vaccine-associated single-nucleotide polymorphisms, including all 5 of the fixed vaccine markers present in nearly all of the strains in the vaccine. The case of herpes zoster was relatively mild and resolved without complications.
我们报告了首例实验室确诊的由Zostavax中减毒水痘带状疱疹病毒(VZV)引起的带状疱疹病例,患者为一名68岁免疫功能正常的成年人,有充分证据表明其既往曾感染野生型VZV。分离株的全基因组序列显示,该毒株携带了42个(36%)已识别的水痘疫苗相关单核苷酸多态性中的15个,包括疫苗中几乎所有毒株都存在的5个固定疫苗标记。该带状疱疹病例相对较轻,未出现并发症即痊愈。